Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Nov;59(Suppl 1):i75–i80. doi: 10.1136/ard.59.suppl_1.i75

Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α

R Williams, M Feldmann, R Maini
PMCID: PMC1766633  PMID: 11053094

Full Text

The Full Text of this article is available as a PDF (151.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Effect of anti-TNFα mAb on clinical progression of established CIA. Arrows indicate time of injection. L2 is an isotype control mAb. (A) Clinical score. The scoring system was based on the following criteria: 0 = normal, 1 = slight swelling and/or erythema, 2 = pronounced oedematous swelling, 3 = ankylosis. Each limb was graded, giving a maximum score of 12 per mouse. (B) Paw swelling. Expressed as the percentage increment in paw width relative to the paw width before the onset of arthritis. Modified from Williams et al.19

Figure 2  .

Figure 2  

Open in a new tab

Histopathological assessment of joints of arthritic DBA/1 mice treated with anti-TNFα. The scoring system was as follows. Mild, minimal synovitis, erosions limited to discrete foci, cartilage surface intact. Moderate, synovitis and erosions present but normal joint architecture intact. Severe, extensive erosions, joint architecture disrupted. Data taken from Williams et al.19

Figure 3  .

Figure 3  

Open in a new tab

Effect of anti-CD4, anti-TNFα and combined anti-CD4/anti-TNFα treatment on the expression of IL1β in the joints of mice with CIA (day 6 of arthritis). Mice were treated on days 1 and 4 of clinical arthritis. On day 6 of arthritis mice were killed and sections of MTP joints were analysed by immunochistochemistry. Each bar represents seven mice, each sampled at four levels throughout the joint—that is, for each cell marker, 28 sections were assessed. The results are expressed as the mean (SEM) number of cells per high power field. Data taken from Marinova-Mutafchieva et al.55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bendele A., McAbee T., Sennello G., Frazier J., Chlipala E., McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 1999 Mar;42(3):498–506. doi: 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  2. Bertolini D. R., Nedwin G. E., Bringman T. S., Smith D. D., Mundy G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986 Feb 6;319(6053):516–518. doi: 10.1038/319516a0. [DOI] [PubMed] [Google Scholar]
  3. Boissier M. C., Feng X. Z., Carlioz A., Roudier R., Fournier C. Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann Rheum Dis. 1987 Sep;46(9):691–700. doi: 10.1136/ard.46.9.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brahn E., Trentham D. E. Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis. Cell Immunol. 1984 Jul;86(2):421–428. doi: 10.1016/0008-8749(84)90397-6. [DOI] [PubMed] [Google Scholar]
  5. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  6. Burmester G. R., Yu D. T., Irani A. M., Kunkel H. G., Winchester R. J. Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum. 1981 Nov;24(11):1370–1376. doi: 10.1002/art.1780241106. [DOI] [PubMed] [Google Scholar]
  7. Butler D. M., Malfait A. M., Mason L. J., Warden P. J., Kollias G., Maini R. N., Feldmann M., Brennan F. M. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol. 1997 Sep 15;159(6):2867–2876. [PubMed] [Google Scholar]
  8. Cavender D., Saegusa Y., Ziff M. Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor. J Immunol. 1987 Sep 15;139(6):1855–1860. [PubMed] [Google Scholar]
  9. Chu C. Q., Field M., Feldmann M., Maini R. N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Sep;34(9):1125–1132. doi: 10.1002/art.1780340908. [DOI] [PubMed] [Google Scholar]
  10. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  11. Courtenay J. S., Dallman M. J., Dayan A. D., Martin A., Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980 Feb 14;283(5748):666–668. doi: 10.1038/283666a0. [DOI] [PubMed] [Google Scholar]
  12. Dayer J. M., Beutler B., Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985 Dec 1;162(6):2163–2168. doi: 10.1084/jem.162.6.2163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  14. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  15. Galfrè G., Milstein C., Wright B. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature. 1979 Jan 11;277(5692):131–133. doi: 10.1038/277131a0. [DOI] [PubMed] [Google Scholar]
  16. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667–8671. doi: 10.1073/pnas.82.24.8667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Geiger T., Towbin H., Cosenti-Vargas A., Zingel O., Arnold J., Rordorf C., Glatt M., Vosbeck K. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol. 1993 Sep-Oct;11(5):515–522. [PubMed] [Google Scholar]
  18. Gregersen P. K., Silver J., Winchester R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987 Nov;30(11):1205–1213. doi: 10.1002/art.1780301102. [DOI] [PubMed] [Google Scholar]
  19. Haworth C., Brennan F. M., Chantry D., Turner M., Maini R. N., Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 1991 Oct;21(10):2575–2579. doi: 10.1002/eji.1830211039. [DOI] [PubMed] [Google Scholar]
  20. Holmdahl R., Andersson M. E., Goldschmidt T. J., Jansson L., Karlsson M., Malmström V., Mo J. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS. 1989 Jul;97(7):575–584. doi: 10.1111/j.1699-0463.1989.tb00446.x. [DOI] [PubMed] [Google Scholar]
  21. Holmdahl R., Jansson L., Larsson E., Rubin K., Klareskog L. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum. 1986 Jan;29(1):106–113. doi: 10.1002/art.1780290114. [DOI] [PubMed] [Google Scholar]
  22. Issekutz A. C., Meager A., Otterness I., Issekutz T. B. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol. 1994 Jul;97(1):26–32. doi: 10.1111/j.1365-2249.1994.tb06574.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Joosten L. A., Helsen M. M., van de Loo F. A., van den Berg W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996 May;39(5):797–809. doi: 10.1002/art.1780390513. [DOI] [PubMed] [Google Scholar]
  24. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025–4031. doi: 10.1002/j.1460-2075.1991.tb04978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kuiper S., Joosten L. A., Bendele A. M., Edwards C. K., 3rd, Arntz O. J., Helsen M. M., Van de Loo F. A., Van den Berg W. B. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 1998 Sep;10(9):690–702. doi: 10.1006/cyto.1998.0372. [DOI] [PubMed] [Google Scholar]
  26. Lewthwaite J., Blake S., Hardingham T., Foulkes R., Stephens S., Chaplin L., Emtage S., Catterall C., Short S., Nesbitt A. Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies. Ann Rheum Dis. 1995 May;54(5):366–374. doi: 10.1136/ard.54.5.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Marinova-Mutafchieva L., Williams R. O., Mason L. J., Mauri C., Feldmann M., Maini R. N. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol. 1997 Mar;107(3):507–512. doi: 10.1046/j.1365-2249.1997.2901181.x. [DOI] [PubMed] [Google Scholar]
  28. Marinova-Mutafchieva L., Williams R. O., Mauri C., Mason L. J., Walmsley M. J., Taylor P. C., Feldmann M., Maini R. N. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum. 2000 Mar;43(3):638–644. doi: 10.1002/1529-0131(200003)43:3<638::AID-ANR21>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  29. Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
  30. Moreland L. W., Heck L. W., Jr, Koopman W. J. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997 Mar;40(3):397–409. doi: 10.1002/art.1780400302. [DOI] [PubMed] [Google Scholar]
  31. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  32. Mori L., Iselin S., De Libero G., Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol. 1996 Oct 1;157(7):3178–3182. [PubMed] [Google Scholar]
  33. Pettipher E. R., Higgs G. A., Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8749–8753. doi: 10.1073/pnas.83.22.8749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Piguet P. F., Grau G. E., Vesin C., Loetscher H., Gentz R., Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology. 1992 Dec;77(4):510–514. [PMC free article] [PubMed] [Google Scholar]
  35. Probert L., Plows D., Kontogeorgos G., Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol. 1995 Jun;25(6):1794–1797. doi: 10.1002/eji.1830250647. [DOI] [PubMed] [Google Scholar]
  36. Qin S., Cobbold S., Tighe H., Benjamin R., Waldmann H. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol. 1987 Aug;17(8):1159–1165. doi: 10.1002/eji.1830170813. [DOI] [PubMed] [Google Scholar]
  37. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rankin E. C., Choy E. H., Kassimos D., Kingsley G. H., Sopwith A. M., Isenberg D. A., Panayi G. S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995 Apr;34(4):334–342. doi: 10.1093/rheumatology/34.4.334. [DOI] [PubMed] [Google Scholar]
  39. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986 Aug 7;322(6079):547–549. doi: 10.1038/322547a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sheehan K. C., Ruddle N. H., Schreiber R. D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol. 1989 Jun 1;142(11):3884–3893. [PubMed] [Google Scholar]
  41. Thorbecke G. J., Shah R., Leu C. H., Kuruvilla A. P., Hardison A. M., Palladino M. A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7375–7379. doi: 10.1073/pnas.89.16.7375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Trentham D. E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 1982 Aug;25(8):911–916. doi: 10.1002/art.1780250801. [DOI] [PubMed] [Google Scholar]
  43. Trentham D. E., Townes A. S., Kang A. H. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977 Sep 1;146(3):857–868. doi: 10.1084/jem.146.3.857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Van Boxel J. A., Paget S. A. Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med. 1975 Sep 11;293(11):517–520. doi: 10.1056/NEJM197509112931101. [DOI] [PubMed] [Google Scholar]
  45. Van Lent P. L., Van De Loo F. A., Holthuysen A. E., Van Den Bersselaar L. A., Vermeer H., Van Den Berg W. B. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol. 1995 Dec;22(12):2250–2258. [PubMed] [Google Scholar]
  46. Vilcek J., Palombella V. J., Henriksen-DeStefano D., Swenson C., Feinman R., Hirai M., Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med. 1986 Mar 1;163(3):632–643. doi: 10.1084/jem.163.3.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  48. Weyand C. M., Hicok K. C., Conn D. L., Goronzy J. J. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801–806. doi: 10.7326/0003-4819-117-10-801. [DOI] [PubMed] [Google Scholar]
  49. Williams R. O., Feldmann M., Maini R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784–9788. doi: 10.1073/pnas.89.20.9784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Williams R. O., Ghrayeb J., Feldmann M., Maini R. N. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology. 1995 Mar;84(3):433–439. [PMC free article] [PubMed] [Google Scholar]
  51. Williams R. O., Mason L. J., Feldmann M., Maini R. N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2762–2766. doi: 10.1073/pnas.91.7.2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Williams R. O. Rodent models of arthritis: relevance for human disease. Clin Exp Immunol. 1998 Dec;114(3):330–332. doi: 10.1046/j.1365-2249.1998.00785.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wooley P. H., Dutcher J., Widmer M. B., Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol. 1993 Dec 1;151(11):6602–6607. [PubMed] [Google Scholar]
  54. Yoo T. J., Kim S. Y., Stuart J. M., Floyd R. A., Olson G. A., Cremer M. A., Kang A. H. Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med. 1988 Aug 1;168(2):777–782. doi: 10.1084/jem.168.2.777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. van de Loo F. A., Joosten L. A., van Lent P. L., Arntz O. J., van den Berg W. B. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 1995 Feb;38(2):164–172. doi: 10.1002/art.1780380204. [DOI] [PubMed] [Google Scholar]
  56. van den Berg W. B., Joosten L. A., Helsen M., van de Loo F. A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol. 1994 Feb;95(2):237–243. doi: 10.1111/j.1365-2249.1994.tb06517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES